LRRK2 and Parkinson disease: Additionally, patients with PD due to the common p.G2019S mutation in Leucine-rich repeat kinase (LRRK2) have excellent motor benefit from DBS, while LRRK2 p.R1441G mutation carriers exhibit worse outcomes than non-carriers [7].